Growth Investing

Late-stage investors want to secure their seats at high growth companies earlier, according to Elisabeth Lind of Cambridge Associates.

The covid-19 pandemic that shut down markets in early 2020 is now helping to lift healthcare investing, which has surged in the first half of 2021, according to a new report by Silicon Valley Bank.

The latest Q2 PitchBook report makes note of how hedge funds and other non-traditional investors are expressing a greater appetite for VC deals in various stages. How long this continues remains to be seen.

With eight exits, including the public offerings of Vroom, Coupang, Wish and Coursera, Alpha Partners co-founder Brian Smiga talks about the firm's approach on investing alongside the pro-rata and what he thinks of opportunity funds and valuations.

The number of examples of early-stage firms raising or talking about creating separate opportunity funds is increasing, which we explore in our latest analysis story.

Rising valuations and other factors have boosted the alternative strategy in recent years as more venture firms consider adding them to their repertoire. So far, LPs are responding positively.

The UK government-backed investor has committed to a growth-equity fund.

Once again, early-stage venture firms are raising or talking about raising separate opportunity funds, or late-stage growth vehicles. How the LP community responds to this latest push will determine how the venture industry looks in the next few years.

Europe’s VC industry had a breakout Q1, on pace for another record-shattering year. Meanwhile, US firms Icon, Sapphire and Sequoia are expanding their operations.

Morrissey's new firm raised $4.5bn for its debut growth fund, which has invested in oat milk producer Oatly and music-to-internet company Epidemic Sound.